Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals.

Chen SS, Michael A, Butler-Manuel SA.

Discov Med. 2012 Jan;13(68):7-17. Review.

2.

Medical therapy of advanced malignant epithelial tumours of the ovary.

Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.

Forum (Genova). 2000 Oct-Dec;10(4):323-32. Review.

PMID:
11535983
3.
4.

Targeted therapy for epithelial ovarian cancer.

Sharma S, Odunsi K.

Expert Opin Ther Targets. 2005 Jun;9(3):501-13. Review.

PMID:
15948670
5.

Advances in the management of epithelial ovarian cancer.

Berkenblit A, Cannistra SA.

J Reprod Med. 2005 Jun;50(6):426-38. Review.

PMID:
16050567
6.

Potential for TRAIL as a therapeutic agent in ovarian cancer.

Abdollahi T.

Vitam Horm. 2004;67:347-64. Review.

PMID:
15110185
7.

Phytochemicals suppress nuclear factor-κB signaling: impact on health span and the aging process.

Salminen A, Kauppinen A, Kaarniranta K.

Curr Opin Clin Nutr Metab Care. 2012 Jan;15(1):23-8. doi: 10.1097/MCO.0b013e32834d3ae7. Review.

PMID:
22108095
8.

Anti-inflammatory plant natural products for cancer therapy.

Aravindaram K, Yang NS.

Planta Med. 2010 Aug;76(11):1103-17. doi: 10.1055/s-0030-1249859. Epub 2010 Apr 29. Review.

PMID:
20432202
9.

Antiangiogenic drugs in the treatment of advanced epithelial ovarian cancer.

Khosravi-Shahi P, Cabezon-Gutierrez L.

Anticancer Agents Med Chem. 2012 Oct 1;12(8):982-7. Review.

PMID:
22263801
10.

Revisiting the complexity of the ovarian cancer microenvironment--clinical implications for treatment strategies.

Musrap N, Diamandis EP.

Mol Cancer Res. 2012 Oct;10(10):1254-64. doi: 10.1158/1541-7786.MCR-12-0353. Epub 2012 Aug 15. Review.

11.

Gene expression and prognostic significance in ovarian cancer.

Tammela J, Odunsi K.

Minerva Ginecol. 2004 Dec;56(6):495-502. Review.

PMID:
15729202
12.

Novel therapies targeting the myeloma cell and its bone marrow microenvironment.

Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC.

Semin Oncol. 2001 Dec;28(6):607-12. Review.

PMID:
11740818
13.

The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models.

Oshima H, Oshima M.

J Gastroenterol. 2012 Feb;47(2):97-106. doi: 10.1007/s00535-011-0523-6. Epub 2012 Jan 5. Review.

PMID:
22218775
14.

Inflammation and ovarian cancer.

Macciò A, Madeddu C.

Cytokine. 2012 May;58(2):133-47. doi: 10.1016/j.cyto.2012.01.015. Epub 2012 Feb 19. Review.

PMID:
22349527
15.

Revisiting the role of antiandrogen strategies in ovarian cancer.

Papadatos-Pastos D, Dedes KJ, de Bono JS, Kaye SB.

Oncologist. 2011;16(10):1413-21. doi: 10.1634/theoncologist.2011-0164. Epub 2011 Sep 23. Review.

16.

The use of plant-derived bioactive compounds to target cancer stem cells and modulate tumor microenvironment.

Pistollato F, Giampieri F, Battino M.

Food Chem Toxicol. 2015 Jan;75:58-70. doi: 10.1016/j.fct.2014.11.004. Epub 2014 Nov 13. Review.

PMID:
25445513
17.

Targeting the tumour microenvironment in ovarian cancer.

Hansen JM, Coleman RL, Sood AK.

Eur J Cancer. 2016 Mar;56:131-43. doi: 10.1016/j.ejca.2015.12.016. Epub 2016 Feb 3. Review.

18.

Cytogenetic analysis of epithelial ovarian cancer's stem cells: an overview on new diagnostic and therapeutic perspectives.

Laganà AS, Colonese F, Colonese E, Sofo V, Salmeri FM, Granese R, Chiofalo B, Ciancimino L, Triolo O.

Eur J Gynaecol Oncol. 2015;36(5):495-505. Review.

PMID:
26513872
19.

Leukaemic stem cells: drug resistance, metastasis and therapeutic implications.

Wong RS, Cheong SK.

Malays J Pathol. 2012 Dec;34(2):77-88. Review.

20.

Biomarkers for ovarian cancer detection and therapy.

Dutta S, Wang FQ, Phalen A, Fishman DA.

Cancer Biol Ther. 2010 May 1;9(9):668-77. Epub 2010 May 24. Review.

PMID:
20372062

Supplemental Content

Support Center